Compare McKesson Corporation (MCK) vs Workiva Inc (WK) Price & Performance

McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.

Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.

Workiva (WK) trades at $71.53, up 1.95% with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and an $86 price target representing 20% upside potential from current levels.

The outlook remains positive with continued earnings growth and AI-driven product expansion driving potential upside. Key risks include high valuation multiples (P/E 85.15) and competitive pressures in the regulatory technology space. The stock's technical positioning near support at $71 suggests near-term stability, while fundamental improvements support longer-term growth prospects.